EIK1001 + Pembrolizumab + Paclitaxel + Pemetrexed + Carboplatin
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout EIK1001 + Pembrolizumab + Paclitaxel + Pemetrexed + Carboplatin
EIK1001 + Pembrolizumab + Paclitaxel + Pemetrexed + Carboplatin is a phase 2 stage product being developed by Eikon Therapeutics for NSCLC. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06246110. Target conditions include NSCLC.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06246110 | Phase 2 | Recruiting |
Competing Products
20 competing products in NSCLC